Presented by PharmaVendor

• February — Oscient Pharmaceuticals (OSCI) cans 100 workers. [check it out]

• March — OSCI says they’re “reaching out to potential strategic partners to explore alternatives.” [check it out]

• May — Deal rumors fuel stock. [check it out]

• June — OSCI axes ALL sales force for its two products, ANTARA and FACTIVE.

OSCI said today it’s giving the boot to its entire sales force of 150 plus 30 additional pink slips handed out among the supporting cast (corporate, marketing detailing, etc.). The axe will swing steadily over the next month says the company.

Since the company has limited cash, it decided to just let the drugs sell themselves and will discontinue direct-selling efforts, but will still keep the drugs on the market.

OSCI had retained Broadpoint Capital to help find a buyer for the two products, or the entire company, but said the process is “still ongoing.”

It’s a troubled time for OSCI. They said if a buyer can’t be found or financing obtained, it may go the way of the DoDo and:

“…take measures to reduce expenses that could lead to seeking bankruptcy protection.”

OSCI has been in our Graveyard for months…

Laid off from OSCI? Send us a tip!

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts